Dexcom director trust sells 4,000 shares in plan

Dexcom Inc. director Mark G. Foletta reported indirect stock sales executed by The Foletta Family Trust under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Dexcom Inc. director Mark G. Foletta reported indirect stock sales executed by The Foletta Family Trust under a pre-arranged Rule 10b5-1 trading plan. On June 15, 2026, the trust sold a total of 4,000 Dexcom common shares in open-market transactions at weighted average prices around $74 per share.

The filing shows two sale blocks: 3,801 shares at a weighted average price of $74.0991 and 199 shares at a weighted average price of $74.8187. Following the transactions, Foletta also reports holding 6,331 Dexcom shares directly.

Insider Trade Summary 10b5-1

Net Seller: 4,000 shares

Net Sell 3 txns

Insider FOLETTA MARK G

Role Director

Sold 4,000 shs ($297K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,801	$74.0991	$282K
Sale	Common Stock	199	$74.8187	$15K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 52,852 shares (Indirect, by Trust); Common Stock — 6,331 shares (Direct)

Footnotes (5)

1. F1. On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.
2. F2. This transaction was executed in multiple trades at prices ranging from $73.70 to $74.685. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
3. F3. Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.
4. F4. This transaction was executed in multiple trades at prices ranging from $74.78 to $75.55. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
5. F5. Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

Key Figures

Total shares sold: 4,000 shares Sale block 1: 3,801 shares at $74.0991 Sale block 2: 199 shares at $74.8187 +2 more

5 metrics

Total shares sold 4,000 shares Net shares sold on June 15, 2026

Sale block 1 3,801 shares at $74.0991 Open-market sale by trust on June 15, 2026

Sale block 2 199 shares at $74.8187 Open-market sale by trust on June 15, 2026

Direct holdings after 6,331 shares Direct Dexcom common stock held after transactions

Net share direction -4,000 shares Net buy/sell shares for this Form 4

Key Terms

Rule 10b5-1 Plan, weighted average sale price, open-market sale, restricted stock units, +1 more

5 terms

Rule 10b5-1 Plan financial

"This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The price above reflects the weighted average sale price."

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

restricted stock units financial

"Represents unvested restricted stock units which were granted on May 28, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

indirect ownership financial

"Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dexcom (DXCM) disclose for Mark G. Foletta?

Dexcom disclosed that director Mark G. Foletta reported indirect sales of 4,000 common shares. The transactions were executed by The Foletta Family Trust in open-market trades on June 15, 2026, at weighted average prices around $74 per share under a 10b5-1 plan.

How many Dexcom (DXCM) shares were sold in the latest Form 4?

The Form 4 reports total sales of 4,000 Dexcom common shares. These consisted of 3,801 shares at a weighted average price of $74.0991 and 199 shares at a weighted average price of $74.8187, all executed in multiple trades on June 15, 2026.

Were Dexcom (DXCM) insider sales by Mark G. Foletta pre-planned?

Yes. The filing states The Foletta Family Trust adopted a Rule 10b5-1 Plan on March 13, 2026. The 4,000 Dexcom shares sold on June 15, 2026, were executed pursuant to this plan, allowing an orderly disposition of trust-owned shares over time.

Who actually holds the Dexcom (DXCM) shares sold in the Form 4?

The sold Dexcom shares are held by The Foletta Family Trust DTD 1/30/2015. The Form 4 explains that shares are held by this trust, with Mark G. Foletta serving as a trustee, so the reported transactions reflect indirect ownership rather than only personal holdings.

What Dexcom (DXCM) holdings does Mark G. Foletta report after the transactions?

After the reported trades, Mark G. Foletta shows 6,331 Dexcom common shares held directly. The filing also lists additional shares held indirectly by The Foletta Family Trust, though the detailed indirect post-transaction total is shown within the transaction table entries.

At what prices were the Dexcom (DXCM) insider sales executed on June 15, 2026?

The filing notes weighted average sale prices of $74.0991 for 3,801 shares and $74.8187 for 199 shares. Footnotes clarify that each block was executed through multiple trades within narrower intraday price ranges on June 15, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 04:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FOLETTA MARK G

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		S		3,801(1)	D	$74.0991(2)	53,051	I	by Trust(3)
Common Stock	06/15/2026		S		199(1)	D	$74.8187(4)	52,852	I	by Trust(3)
Common Stock								6,331(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.

2. This transaction was executed in multiple trades at prices ranging from $73.70 to $74.685. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

3. Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.

4. This transaction was executed in multiple trades at prices ranging from $74.78 to $75.55. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

5. Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Mark G. Foletta	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)